Taiwan · Delayed Price · Currency is TWD Bonraybio Statistics
Total Valuation
Bonraybio has a market cap or net worth of TWD 2.98 billion. The enterprise value is 2.45 billion.
| Market Cap | 2.98B |
| Enterprise Value | 2.45B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | Mar 19, 2026 |
Share Statistics
Bonraybio has 30.38 million shares outstanding. The number of shares has decreased by -6.76% in one year.
| Current Share Class | 30.38M |
| Shares Outstanding | 30.38M |
| Shares Change (YoY) | -6.76% |
| Shares Change (QoQ) | +22.48% |
| Owned by Insiders (%) | 8.30% |
| Owned by Institutions (%) | 2.23% |
| Float | 10.56M |
Valuation Ratios
The trailing PE ratio is 27.65.
| PE Ratio | 27.65 |
| Forward PE | n/a |
| PS Ratio | 8.96 |
| PB Ratio | 4.53 |
| P/TBV Ratio | 4.71 |
| P/FCF Ratio | 38.84 |
| P/OCF Ratio | 30.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.68, with an EV/FCF ratio of 31.92.
| EV / Earnings | 22.65 |
| EV / Sales | 7.36 |
| EV / EBITDA | 20.68 |
| EV / EBIT | 23.22 |
| EV / FCF | 31.92 |
Financial Position
The company has a current ratio of 9.98, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.98 |
| Quick Ratio | 8.97 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.07 |
| Interest Coverage | 948.87 |
Financial Efficiency
Return on equity (ROE) is 17.39% and return on invested capital (ROIC) is 99.55%.
| Return on Equity (ROE) | 17.39% |
| Return on Assets (ROA) | 9.70% |
| Return on Invested Capital (ROIC) | 99.55% |
| Return on Capital Employed (ROCE) | 15.99% |
| Weighted Average Cost of Capital (WACC) | 4.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, Bonraybio has paid 9.31 million in taxes.
| Income Tax | 9.31M |
| Effective Tax Rate | 7.94% |
Stock Price Statistics
The stock price has decreased by -24.23% in the last 52 weeks. The beta is 0.07, so Bonraybio's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -24.23% |
| 50-Day Moving Average | 98.94 |
| 200-Day Moving Average | 123.87 |
| Relative Strength Index (RSI) | 70.51 |
| Average Volume (20 Days) | 12,359 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bonraybio had revenue of TWD 332.21 million and earned 107.98 million in profits. Earnings per share was 3.54.
| Revenue | 332.21M |
| Gross Profit | 257.03M |
| Operating Income | 105.33M |
| Pretax Income | 117.29M |
| Net Income | 107.98M |
| EBITDA | 114.99M |
| EBIT | 105.33M |
| Earnings Per Share (EPS) | 3.54 |
Balance Sheet
The company has 535.64 million in cash and 5.26 million in debt, with a net cash position of 530.38 million or 17.46 per share.
| Cash & Cash Equivalents | 535.64M |
| Total Debt | 5.26M |
| Net Cash | 530.38M |
| Net Cash Per Share | 17.46 |
| Equity (Book Value) | 656.72M |
| Book Value Per Share | 21.62 |
| Working Capital | 575.79M |
Cash Flow
In the last 12 months, operating cash flow was 96.71 million and capital expenditures -20.08 million, giving a free cash flow of 76.62 million.
| Operating Cash Flow | 96.71M |
| Capital Expenditures | -20.08M |
| Depreciation & Amortization | 9.67M |
| Net Borrowing | -3.33M |
| Free Cash Flow | 76.62M |
| FCF Per Share | 2.52 |
Margins
Gross margin is 77.37%, with operating and profit margins of 31.70% and 32.50%.
| Gross Margin | 77.37% |
| Operating Margin | 31.70% |
| Pretax Margin | 35.31% |
| Profit Margin | 32.50% |
| EBITDA Margin | 34.61% |
| EBIT Margin | 31.70% |
| FCF Margin | 23.06% |
Dividends & Yields
This stock pays an annual dividend of 1.22, which amounts to a dividend yield of 1.17%.
| Dividend Per Share | 1.22 |
| Dividend Yield | 1.17% |
| Dividend Growth (YoY) | 15.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 34.45% |
| Buyback Yield | 6.76% |
| Shareholder Yield | 7.93% |
| Earnings Yield | 3.63% |
| FCF Yield | 2.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 25, 2025. It was a forward split with a ratio of 1.15.
| Last Split Date | Aug 25, 2025 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
Bonraybio has an Altman Z-Score of 38.41 and a Piotroski F-Score of 3.
| Altman Z-Score | 38.41 |
| Piotroski F-Score | 3 |